Report cover image

Fibromyalgia Therapeutics Market by Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 183 Pages
SKU # IRE18443547

Description

Fibromyalgia Therapeutics Market by Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Global Forecast 2024-2030


The Fibromyalgia Therapeutics Market size was estimated at USD 3.47 billion in 2023 and expected to reach USD 3.67 billion in 2024, at a CAGR 5.07% to reach USD 4.91 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Fibromyalgia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Fibromyalgia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Fibromyalgia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Jazz Pharmaceuticals plc, Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, and Viatris inc..

Market Segmentation & Coverage



This research report categorizes the Fibromyalgia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Antidepressants
Antiepileptic
Muscle Relaxants
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Fibromyalgia Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Fibromyalgia Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Fibromyalgia Therapeutics Market?
4. What is the market share of the leading vendors in the Fibromyalgia Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Fibromyalgia Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

183 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Fibromyalgia Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of fibromyalgia worldwide
5.1.1.2. Rise in the number of clinical trials to determine causes and efficacy of fibromyalgia therapeutics
5.1.1.3. Inclination toward early diagnosis and treatment of diseases
5.1.2. Restraints
5.1.2.1. High cost associated with fibromyalgia treatment
5.1.3. Opportunities
5.1.3.1. Emphasis on personalized medicine for targeted and effective fibromyalgia therapies
5.1.3.2. Ongoing R&D for the development of efficient drugs for fibromyalgia
5.1.4. Challenges
5.1.4.1. Concerns associated with inaccurate diagnosis of fibromyalgia
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Fibromyalgia Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Antidepressants
6.3. Antiepileptic
6.4. Muscle Relaxants
7. Fibromyalgia Therapeutics Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy
8. Americas Fibromyalgia Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Fibromyalgia Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Fibromyalgia Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Amgen Inc.
12.1.3. Amicus Therapeutics
12.1.4. Astellas Pharma Inc
12.1.5. AstraZeneca plc
12.1.6. Bayer AG
12.1.7. Biogen Inc.
12.1.8. BioMarin Pharmaceutical Inc
12.1.9. C.H. Boehringer Sohn AG & Co. KG
12.1.10. Eli Lilly and Company
12.1.11. Gilead Sciences, Inc.
12.1.12. GlaxoSmithKline (GSK)
12.1.13. Jazz Pharmaceuticals plc
12.1.14. Johnson & Johnson Services, Inc.
12.1.15. Kyowa Kirin Co, Ltd
12.1.16. Merck & Co., Inc.
12.1.17. Novartis AG
12.1.18. Pfizer inc.
12.1.19. Regeneron Pharmaceuticals, Inc.
12.1.20. Roche Holding AG
12.1.21. Sanofi S.A.
12.1.22. Sarepta Therapeutics, Inc.
12.1.23. Takeda Pharmaceutical Company
12.1.24. Teva Pharmaceutical Industries Ltd.
12.1.25. The Bristol-Myers Squibb Company
12.1.26. Vertex Pharmaceuticals Incorporated
12.1.27. Viatris inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. FIBROMYALGIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. FIBROMYALGIA THERAPEUTICS MARKET DYNAMICS
FIGURE 7. FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us